Biotech Business - July 30, 2025
Oncopeptides partners with SD Pharma
SD Pharma is a Spanish pharmaceutical broker specializing in oncology and hematology and this partnership will broaden physician reach of Pepaxti across hospital channels throughout Spain, states Oncopeptides.
New Market - July 2, 2025
Camurus’ Oczyesa receives marketing authorization in the EU
Camurus has announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.
Digital health - June 10, 2025
Mavatar establishes US presence
Swedish Mavatar has announced the opening of its first US office and the upcoming commercial launch of its platform Mavatar Discovery.
Biotech Business - April 15, 2025
EU approves Leqembi for treatment of early Alzheimer’s disease
The European Commission has granted BioArctic’s partner Eisai’s application for Marketing Authorization of Leqembi (lecanemab) in the European Union (EU).
Agreement - April 14, 2025
OncoZenge in agreement for BupiZenge in the GCC Region
OncoZenge and Avernus Pharma General Trading, a pharma marketing company from the UAE, have signed an exclusive agreement to license BupiZenge for commercialization and distribution in the Gulf Cooperation Council (GCC) region.
New Market - February 10, 2025
Boule Diagnostics enters distribution agreement
Boule Diagnostics has entered into an exclusive distribution agreement with VitalScientific for the US market.
